{"entity":{"id":"nct07016997","kind":"trial","name":"A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.","aka":[],"tldr":"A phase 1 trial of CBA-1535 run by Chiome Bioscience Inc., now recruiting.","summary":"A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. is a phase 1 interventional study registered as NCT07016997 by Chiome Bioscience Inc., with 70 participants planned, started 2022-06-27. Conditions recorded: Solid Tumors and Refractory Cancer. Interventions recorded: CBA-1535 and CBA-1535+Pembrolizumab.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07016997","url":"https://clinicaltrials.gov/study/NCT07016997"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cba-1535"],"companies":["chiome-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07016997","phase":"1","setting":"A Phase I Study to Assess the Safety, Tolerability and Biomarker Profiles of CBA-1535, Recombinant Protein Tribody in Patients With Previously Treated Advanced Solid Tumors.","sponsor":"Chiome Bioscience Inc.","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07016997/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cba-1535","kind":"drug","name":"CBA-1535","route":"/drugs/cba-1535/"}],"company":[{"id":"chiome-bioscience","kind":"company","name":"Chiome Bioscience","route":"/companies/chiome-bioscience/"}]}}